Lipocine's LPCN 1148 for cirrhosis highlighted in Hepatology journal

Lipocine Inc.

LPCN 1148 for men with cirrhosis featured in 'Hepatology Highlights' in June 2025 edition of Hepatology.
Article contributed by Dr. Kevin Harris of Mayo Clinic; Phase 2 results published in same issue.
FDA granted fast track designation for LPCN 1148 as treatment for sarcopenia in decompensated cirrhosis.
CEO Mahesh Patel highlighted growing recognition of LPCN 1148's potential to improve cirrhosis outcomes.
Company is exploring partnering opportunities for LPCN 1148.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.